1-2 of 2
Ryo Atsumi, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Satoko Morishima, MD PhD, Kenji Ishitsuka, MD PhD, Koji Izutsu, MD PhD, Shigeru Kusumoto, MD PhD, Junya Makiyama, MD PhD, Atae Utsunomiya, MD, Kisato Nosaka, MD PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD PhD, Nobuhiko Yamauchi, MD, Kazushi Araki, DVM, PhD, Nobuaki Adachi, PhD, Tomonari Yamashita, Ryo Atsumi, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4025.
https://doi.org/10.1182/blood-2019-125507
Published: 2019
Journal Articles

Population Pharmacokinetic and Exposure-Response Modeling for the EZH1/2 Dual Inhibitor DS-3201b in Patients with Non-Hodgkin Lymphomas

Ryo Atsumi, PhD, Satoshi Yoshiba, Dai Maruyama, MD PhD, Kensei Tobinai, MD PhD, Takashi Ishida, MD PhD, Kenji Ishitsuka, MD PhD, Yoshitaka Imaizumi, MD PhD, Shogo Takeuchi, MD, Kunihiro Tsukasaki, MD PhD, Nobuaki Adachi, PhD, Sumiaki Fujitani, MSc, Masaya Tachibana, PhD, Kazutaka Yoshihara, Hitoshi Ishizuka, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2544.
https://doi.org/10.1182/blood.V130.Suppl_1.2544.2544
Published: 2017